AGENDA

Subject to change

7:00–8:00 am

Breakfast and Registration*

Session 1: Defining Cirrhosis: Clinical, Histologic, and Radiologic

Moderators: Laurent Castera, MD; Manuel Romero-Gomez, MD; Elisa Pose, MD, PhD

8:00–8:05 am

Welcome Address

Rohit Loomba, MD, MHSc

8:05–8:20 am

Clinical Diagnosis of Cirrhosis in Liver Clinic 2026 Including Imaging CT and MRI

Patrick S. Kamath, MD

8:20–8:35 am

Histologic Diagnosis of MASH Cirrhosis and Definition for Regression of Cirrhosis Role of AI Base Assessment of Liver

David E. Kleiner, MD, PhD

8:35–8:50 am

Cirrhosis Based Upon: Specific Cut Point- Elastography- role of VCTE, MRE, cT1, ELF, Fibrospect 2, Pro-C3, ADAPT, Anticipate- MASH

Mazen Noureddin MD, MHSc

8:50–9:05 am

Genetic Risk Score in Cirrhosis and Outcomes and Treatment Response by Gentotype

Naga Chalasani, MD

9:05–9:25 am

Serpina 1 and PiZZ and MZ- Identification, Treatment Landscape- Clinical Trial Consideration, and Endpoints

Pavel Strnad, MD

9:25–9:40 am

Panel Discussion

9:40–10:10 am

Coffee Break*

Session 2: Cirrhosis Biomarkers: From Research to Trials to Clinical Practice

Moderators: Veeral Ajmera, MD, MAS; Mads Israelsen, MD, PhD

10:10–10:25 am

NIT Based Inclusion Criteria

Vincent Wong, MBChB (Hons), MD, FRCP, FHKCP, FHKAM

10:25–10:35 am

GOLDMINE Study Update and MALO

Suzanne Sharpton, MD

10:35–10:50 am

LSM- As Reasonably Likely Surrogate Endpoint

Rohit Loomba, MD, MHSc

10:50–11:05 am

Impact of Obesity on LSM- Treatment Response Within and its Impact on LSM

Veeral Ajmera, MD, MAS

11:05–11:15 am

BAVENO VIII Update for Cirrhosis Due to MASH, MetALD and ALD

Virginia Hernandez, MD

11:15–11:30 am

Debate: Should You Include Patients With Small Varices in Cirrhosis Trials? Focus on Definition of Varices Needing Treatment as an Outcome–FDA versus EMA

11:15–11:20 am Pro: Guadalupe Garcia-Tsao

11:20–11:25 am Con: Naim Alkhouri, MD

11:25–11:50 pm

Panel Discussion

11:50 am–1:00 pm

Lunch*

12:15–1:00 pm

Industry-Sponsored Event*

Session 3: New Data and Insights on Cirrhosis, and MALO

Moderators: Zobair M. Younossi, MD, MPH, FACG, FACP, AGAF, FAASLD; Amreen Dinani, MD, FRCPC, ABOM

1:00–1:10 pm

NIT Diagnosis of MASH Cirrhosis—Delphi Panel

Luis Antonio Diaz Piga, MD

1:10–1:20 pm

Pro-C3 and Cell Free DNA as Biomarker for MASH, Cirrhosis and GLP-1 Response

1:20–1:30 pm

Cell Free DNA and Others Biomarkers for HCC in Cirrhosis

Amit Singal, MD

1:30–1:35 pm

Oral Abstract 1

1:35–1:40 pm

Oral Abstract 2

1:40–1:45 pm

Question and Answer

1:45–2:00 pm

Key Concepts in MALO and Definitions of Each Outcome: Ascites, Varices Needing Treatment, HE, MELD 15

Jerome Boursier, MD

2:00–2:15 pm

Debate: MASH, MetALD and ALD Cirrhosis Trials:

Universal Carvedilol for All Based Upon Baveno VII

2:00–2:05 pm Pro: Thomas Reiberger, MD

2:05–2:10 pm Con: Aleksander Krag, MD, PhD, MBA

2:10–2:15 pm Tie Breaker

2:15–2:35 pm

Regulatory Considerations for the Use of Non-Invasive Biomarkers in MASH Cirrhosis Trials: FDA Perspective

2:35–2:55 pm

Panel Discussion

2:55–3:10 pm

Coffee Break*

Session 4: AI, Emerging Issues in Other Liver Diseases—ALD, PBC and PSC, Cirrhosis

Moderators: Daniel Huang, MD; Marina Serper, MD, MS; Monica Tincopa, MD, MS

3:10–3:20 pm

Lessons Learned From PNPLA3 and HSD17B13 Trials

3:20–3:30 pm

Artificial Intelligence Applications in Improving Outcomes in Cirrhosis

Jin Ge, MD, MBA

3:30–3:45 pm

PBC and PSC: Approved Therapies, Trial Endpoints, and the Pipeline

Gideon Hirschfield, MD

3:45–4:00 pm

Trial Design and Outcomes: MAESTRO NASH Cirrhosis, FGF-21 Cirrhosis Trials, Survodutide Cirrhosis Trials

4:00–4:15 pm

Key Considerations in Cirrhosis Trials Design and Outcome Assessment in 2026

Vlad Ratziu, MD, PhD

4:15–4:35 pm

Emerging Trials and Endpoints for MetALD and ALD

Juan Pablo Arab, MD

4:35–4:50 pm

Leveraging Multi-Omic Technologies to Inform Biomarker Discovery/Validation in Cirrhosis Trials

4:50–5:00 pm

Closing Remarks

Rohit Loomba, MD, MHSc

*Non-accredited session